Global Search for a Cancer Cure Drives Market for Benda Pharmaceutical`s Gene Therapy Medicine
Released on: October 9, 2007, 9:22 am
Press Release Author: InvestorIdeas.com
Industry: Pharmaceuticals
Press Release Summary: China-AsiaStocks.com Profiles New Showcase China Stock for Investors Following Sector; Benda Pharmaceutical, Inc., Producer of Conventional and Traditional Chinese Medicines
Press Release Body: POINT ROBERTS, Wash., Delta B.C., October 9, 2007 - InvestorIdeas.com and China-AsiaStocks.com, its investor and industry portal focused on the China-Asia sector, announce China-based pharmaceutical company, Benda Pharmaceutical, Inc. (OTCBB: BPMA), as a new showcase company. Benda is involved in the production of both conventional and Traditional Chinese Medicines and most notably is responsible for the production of Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer.
China, a nation that is facing escalating cancer rates, heart disease and an aging population, is currently exploring options for significantly reforming its health system in an effort to provide improved access to affordable health treatment and services. The Country's healthcare challenges have been driving growth in its pharmaceutical and biotech market, leading many to believe that China has the potential to become the world's fifth largest drug market by 2010.
Benda Pharmaceutical owns and operates five plants combining to produce more than thirty medicines and medicine ingredients, including the addition of the gene therapy cancer medicine, Gendicine®, acquired through its purchase of SiBiono Genetech Corp, the developers of this promising treatment.
According to the Company, Gendicine®, supplemented by radiotherapy, chemotherapy or heat treatment, raises treatment efficacy to 3x that of all other tumor treatment methods. In clinical trials for 135 patients affected by head and neck tumors, 64% had their tumors eliminated after one month of Gendicine® treatment, marking a 340% increase in efficacy relative to traditional treatments.
Benda Pharmaceutical is working to build their presence within the fast growing Chinese market and forecasts that Gendicine® will generate $20.8 million in revenue in 2008 up from estimates of $12 million for 2007. In total, the Company anticipates revenues to reach $40.7 million in 2007 and progressing upwards to $76.2 million in 2008.
For Additional Information Visit: http://www.investorideas.com/co/bpma/
Benda Pharmaceutical Inc. is a Showcase Company on InvestorIdeas.com. Compensation is disclosed in disclaimer below.
About InvestorIdeas.com: InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, Middle East and Australia. China-AsiaStocks.com is an investor portal within InvestorIdeas.com covering news and market info, as well as a growing directory of stocks in the sector. InvestorIdeas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Benda Pharmaceutical, Inc. (OTCBB: BPMA) $4000USD per month. For More Information Contact: Dawn Van Zant 800-665-0411 Email: dvanzant@investorideas.com
2022
